Works matching IS 18696953 AND DT 2022 AND VI 13 AND IP 6
Results: 11
Acute Administration of the GLP-1 Receptor Agonist Lixisenatide Diminishes Postprandial Insulin Secretion in Healthy Subjects But Not in Type 2 Diabetes, Associated with Slowing of Gastric Emptying.
- Published in:
- Diabetes Therapy, 2022, v. 13, n. 6, p. 1245, doi. 10.1007/s13300-022-01258-4
- By:
- Publication type:
- Article
Bioequivalence Studies of New Generic Formulations of Vildagliptin and Fixed-Drug Combination of Vildagliptin and Metformin Versus Respective Originator Products in Healthy Volunteers.
- Published in:
- Diabetes Therapy, 2022, v. 13, n. 6, p. 1215, doi. 10.1007/s13300-022-01269-1
- By:
- Publication type:
- Article
Study Design and Baseline Characteristics of Patients with T2DM in the Post-marketing Safety Study of Dulaglutide in China (TRUST-CHN).
- Published in:
- Diabetes Therapy, 2022, v. 13, n. 6, p. 1231, doi. 10.1007/s13300-022-01268-2
- By:
- Publication type:
- Article
Efficacy and Safety of LY2963016 Insulin Glargine in Chinese Patients with Type 1 Diabetes Previously Treated with Insulin Glargine (Lantus<sup>®</sup>): a Post Hoc Analysis of a Randomized, Open-Label, Phase 3 Trial.
- Published in:
- Diabetes Therapy, 2022, v. 13, n. 6, p. 1161, doi. 10.1007/s13300-022-01262-8
- By:
- Publication type:
- Article
Reductions in HbA1c with Flash Glucose Monitoring Are Sustained for up to 24 Months: A Meta-Analysis of 75 Real-World Observational Studies.
- Published in:
- Diabetes Therapy, 2022, v. 13, n. 6, p. 1175, doi. 10.1007/s13300-022-01253-9
- By:
- Publication type:
- Article
Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in Patients with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the UK.
- Published in:
- Diabetes Therapy, 2022, v. 13, n. 6, p. 1203, doi. 10.1007/s13300-022-01267-3
- By:
- Publication type:
- Article
Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Insulin-Naïve People with Type 2 Diabetes: the ATOS Study.
- Published in:
- Diabetes Therapy, 2022, v. 13, n. 6, p. 1187, doi. 10.1007/s13300-022-01266-4
- By:
- Publication type:
- Article
Profile of Patients with Diabetes Treated with Insulin Lispro 200 U/ml: A Real-World Study from Spain.
- Published in:
- Diabetes Therapy, 2022, v. 13, n. 6, p. 1147, doi. 10.1007/s13300-022-01264-6
- By:
- Publication type:
- Article
Oral Semaglutide: Dosage in Special Situations.
- Published in:
- Diabetes Therapy, 2022, v. 13, n. 6, p. 1133, doi. 10.1007/s13300-022-01265-5
- By:
- Publication type:
- Article
Correction to: Effectiveness in Real World of Once Weekly Semaglutide in People with Type 2 Diabetes: Glucagon-Like Peptide Receptor Agonist Naïve or Switchers from Other Glucagon-Like Peptide Receptor Agonists: Results from a Retrospective Observational Study in Umbria
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Measuring the Impact of Flash Glucose Monitoring in a Pediatric Population in Saudi Arabia: A Retrospective Cohort Study.
- Published in:
- Diabetes Therapy, 2022, v. 13, n. 6, p. 1139, doi. 10.1007/s13300-022-01224-0
- By:
- Publication type:
- Article